Introduction
============

iTeos leverages the science of the LICR to target the metabolism of the tumor microenvironment and develops small-molecule inhibitors. Tryptophan catabolism can suppress the anti-tumor immune response through expression of the rate-limiting enzyme IDO1. Local tryptophan reduction and metabolite production by the kynurenine pathway are associated with anergy/apoptosis of tumor-infiltrating lymphocytes. Two IDO1 inhibitors (Incyte INCB24360/NewLink NLG919) are currently tested in clinical trials for treatment of relapsed/refractory solid tumors but exhibit therapeutic limitations.

Methods/results
===============

A primary HTS (176,000 compounds) led to the discovery of several confirmed hits. Medicinal chemistry optimization resulted in an original lead with nM potency in a relevant human blood assay, comparable to Incyte IDO1~i~(IC~50~890 ± 220 nM \[iTeos IDO1~i~\] versus 970 ± 100 nM \[Incyte IDO1~i~\] \[N = 3 donors; Kyn ELISA\]). For rodents & monkey, iTeos compound showed low clearance (9.9&1.9 mL/min/kg respectively), moderate-to-low protein binding (48&28%Fu respectively), a short half-life in rodents but long in monkey (1.1&12 h respectively), good oral availability (\>75%), and no inhibition on five CYP450 isoforms). Good predictive values for human PK were obtained through allometric scaling. Quantification of the tryptophan metabolite kynurenine showed a significant decrease in mouse plasma after oral administration of the IDO1~i~in a dose response setting (45.3 ± 2.4 \[iTeos IDO1~i~\] and 48.1% ± 3.0 \[Incyte IDO1~i~\]; 2 h per os at 100 mg/kg compared to vehicle; N = 5 independent experiments). In a time-course experiment, inhibition of kynurenine production lasted 8 h (iTeos IDO1~i~) compared to 16 h (Incyte IDO1~i~), consistent with their respective rodent half-life. A comparable PD effect was observed in mouse tumor lysates. Monkey PD is ongoing. Preliminary data obtained with the Pan02 mouse tumor model showed significant survival benefit of the iTeos IDO1~i~in stand-alone and in combination with anti-CTLA4 treatment compared to vehicle or anti-CTLA4 in stand-alone respectively. 15 different human cancer types (60 samples each) were analyzed for IDO1 protein expression and allowed identification of several tumors with high expression.

Conclusions
===========

iTeos\' drug discovery efforts have delivered a selective IDO1 small-molecule inhibitor with novel scaffold suitable for *in vitro*/*in vivo*validation and with good predictive human PK (low clearance(\<10% Q~H~), long half-life(\>20 h), high oral bioavailability).
